Longitudinal Perceptions of Prognosis and Goals of Therapy in Patients With Metastatic Non–Small-Cell Lung Cancer: Results of a Randomized Study of Early Palliative Care The Study of Tamoxifen and ...
The drug development process necessitates the comprehensive evaluation of a candidate’s therapeutic benefits alongside its potential risks. Benefit–risk assessments are central to this endeavour, ...
In oncology drug development, using biomarkers to select a study population more likely to benefit from a therapeutic effect is critical to increase the efficiency of a clinical trial in demonstrating ...
When outcome selection and prioritisation are defined early in development, the evidence base supports continuity from trial ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An increased ...
US market availability for Tavneos continues as Amgen works with the FDA to address concerns over trial data assessment and known hepatotoxicity risks. Amgen is providing prescribers with updated ...
(RTTNews) - The FDA has announced Makena and its generics are no longer approved and cannot lawfully be distributed in interstate commerce. The drug that had been approved under the accelerated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results